CoChat

Nonalcoholic fatty liver disease is an increasing indication for liver transplantation in the Nordic countries

Open access
Holmer, Magnus, Melum, Espen, Isoniemi, Helena, Ericzon, Bo‐Göran, Castedal, Maria, Nordin, Arno, Aagaard Schultz, Nicolai, Rasmussen, Allan, Line, Pål‐Dag, Stål, Per, Bennet, William, Hagström, Hannes · 2018 · Liver International
Cited by 66

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Background & Aims: Nonalcoholic fatty liver disease(NAFLD) is the second most common cause of liver transplantation in the US. Data on NAFLD as a liver transplantation indication from countries with lower prevalences of obesity are lacking. We studied the temporal trends of NAFLD as an indication for liver transplantation in the Nordic countries, and compared outcomes for patients with NAFLD to patients with other indications for liver transplantation. Method: Population‐based cohort study using data from the Nordic Liver Transplant Registry on adults listed for liver transplantation between 1994 and 2015. NAFLD as the underlying indication for liver transplantation was defined as a listing diagnosis of NAFLD/nonalcoholic steatohepatitis, or cryptogenic cirrhosis with a body mass index ≥25 kg/m 2 and absence of other liver diseases. Waiting time for liver transplantation, mortality and withdrawal from the transplant waiting list were registered. Survival after liver transplantation was calculated using multivariable Cox regression, adjusted for age, sex, body mass index and model for end‐stage liver disease. Results: A total of 4609 patients listed for liver transplantation were included. NAFLD as the underlying indication for liver transplantation increased from 2.0% in 1994‐1995 to 6.2% in 2011‐2015 (P = .01) and was the second most rapidly increasing indication. NAFLD patients had higher age, model for end‐stage liver disease and body mass index when listed for liver transplantation, but overall survival after liver transplantation was comparable to non‐‐NAFLD patients (aHR 1.03, 95% CI 0.70‐1.53 P = .87). Conclusion: NAFLD is an increasing indication for liver transplantation in the Nordic countries. Despite more advanced liver disease, NAFLD patients have a comparable survival to other patients listed for liver transplantation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/liv.13751

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 66

Metadata

Authors
Holmer, M., Melum, E., Isoniemi, H., Ericzon, B., Castedal, M., Nordin, A., Aagaard Schultz, N., Rasmussen, A., Line, P., Stål, P., Bennet, W., & Hagström, H.
Venue
Liver International
Publisher
Wiley
Published
2018-05-02
Volume
38
Issue
11
Pages
2082-2090
ISSN
  • 0106-9543 (ISSN-L)
  • 1478-3223
  • 1478-3231
OpenAlex
W2796469285
Cited by
66
References
6
FWCI
6.83
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nonalcoholic fatty liver disease is an increasing indication for liver transplantation in the Nordic countries. https://app.cochat.ai/papers/10.1111/liv.13751
The paper
Holmer, M., Melum, E., Isoniemi, H., Ericzon, B., Castedal, M., Nordin, A., Aagaard Schultz, N., Rasmussen, A., Line, P., Stål, P., Bennet, W., & Hagström, H. (2018). Nonalcoholic fatty liver disease is an increasing indication for liver transplantation in the Nordic countries. Liver International. https://doi.org/10.1111/liv.13751

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.